- Home
- XERS vs REX Comparison
XERS vs REX Comparison
Compare XERS & REX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XERS | REX |
|---|---|---|
| Founded | 2005 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2021 | 1994 |
Fundamental Metrics
Financial Performance| Metric | XERS | REX |
|---|---|---|
| Price | $8.23 | $43.04 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $10.83 | N/A |
| AVG Volume (30 Days) | ★ 1.9M | 140.3K |
| Earning Date | 05-07-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | N/A |
| EPS | 0.01 | ★ 0.56 |
| Revenue | $49,590,000.00 | ★ $650,487,000.00 |
| Revenue This Year | $34.37 | $19.45 |
| Revenue Next Year | $22.86 | N/A |
| P/E Ratio | $821.00 | ★ $78.14 |
| Revenue Growth | ★ 142.67 | 1.24 |
| 52 Week Low | $4.87 | $30.02 |
| 52 Week High | $10.08 | $64.95 |
Technical Indicators
Market Signals| Indicator | XERS | REX |
|---|---|---|
| Relative Strength Index (RSI) | 54.38 | 36.49 |
| Support Level | $8.00 | $41.97 |
| Resistance Level | $8.42 | $48.91 |
| Average True Range (ATR) | 0.33 | 1.38 |
| MACD | -0.11 | -0.38 |
| Stochastic Oscillator | 24.00 | 7.12 |
Price Performance
Historical ComparisonAbout XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
About REX REX American Resources Corporation
REX American Resources Corp operates as a holding company that engages in investments in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include Ethanol, dried distillers grains, modified distillers grains, Distillers corn oil, Modified distillers grains, and Other.